QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advaxis, Inc. (ADXS) Makes It Bad To Be A Cancer Cell 0 comments
    Feb 5, 2013 5:34 PM | about stocks: ADXS

    Advaxis, a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases, is developing a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to the cancer itself.

    The company's approach has been determined to outsmart tumor protection reactions that foil other treatments, while also generating a long-term immune system "memory" that is able to hunt down cancer cells throughout the body beyond the initially targeted antigens. And, being an immunotherapy, it does it all without the poisons and associated side effects of traditional chemotherapy treatments.

    Advaxis immunotherapies are designed to stimulate many complementary immune mechanisms of action, including:

    • Strong innate immune effects

    • Strong adaptive immune effects

    • Reduction of both Tregs and MDSCs in tumors but not in other tissues or systemically

    • Memory generation that is not impaired by antibiotics administered immediately after dosing

    • Chemotaxis and extravasation of activated immune cells

    • Upregulation of tumor chemokines and chemokines receptors

    • Epitope and antigen spreading

    • A predominantly cellular immune response with little antibody formation

    Over 15 distinct constructs are in various stages of development, either developed directly by Advaxis or through strategic collaborations with recognized centers of excellence, such as the National Cancer Institute. The company's first construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer). In addition, Advaxis has developed immunotherapies for prostate cancer and HER2 expressing cancers (such as breast, gastric, bladder, brain, pancreatic, ovarian cancer, and canine osteosarcoma).

    For additional information, visit Advaxis.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.